Mursla Bio Information

Mursla Bio is a UK- and Boston–based precision medicine and diagnostics company spun out of the University of Cambridge. The company has developed a clinically validated, AI-enabled platform that analyzes tissue-specific extracellular vesicles (TS-EVs) from blood to deliver tissue-resolved, multiomic insights not accessible through standard liquid biopsy approaches. Mursla’s initial focus is liver disease, where its lead program, EvoLiver™, is the only FDA Breakthrough-designated blood test for liver cancer surveillance for 7 years. EvoLiver leverages a capital-efficient, hepatology-led pathway to enable guideline-driven adoption and reimbursement. Beyond liver cancer surveillance, Mursla is advancing precision medicine partnerships in metabolic liver disease (MASH), anchored by a landmark big pharma collaboration, and selectively expanding its platform to additional organs.